Bronchial Arterial Infusion Plus Bronchial Arterial Chemoembolization (BAI-BACE) for Advanced Lung Squamous Cell Carcinoma: a Multicenter Single-arm Phase II Study
Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma.
• Squamous cell carcinoma diagnosed by pathology, and central location by imaging;
• Age 18-80;
• Patients failed to the standard first-line or second-line treatment;
• Tumors limited in the chest;
• Tumors were fed by bronchial artery through CTA reconstruction;
• Patents received PD-1 inhibitor or not were also included;
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2;
• Images within 2 weeks before inclusion;
• Life expectancy more than 3 months;
⁃ Agreed to participated in this clinical trial;
⁃ Hemameba ≥3.0 x109/L, neutrophil ≥1.5x109/L, hemoglobin≥10.0 g/L, platelet≥100x 109/L, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml/min.